Milestone Scientific (MLSS)
XASE:MLSS
Top Page
Milestone Scientific
(NYSE MKT:MLSS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.29
▲(0.69% Upside)
Action:ReiteratedDate:04/03/26
The score is held down primarily by weak financial performance (ongoing losses, persistent cash burn, and a shrinking equity cushion). Technical indicators are mildly supportive near-term but the longer-term trend remains unfavorable. Guidance and commercial initiatives provide some upside potential, and improved financing flexibility helps, but near-term liquidity and execution risk remain key constraints.
Positive Factors
High Gross Margins
Sustained gross margins near 70% indicate the core products have durable unit economics and pricing power. If management controls SG&A and R&D, high gross margins create a realistic path to profitability as volumes scale, supporting long-term margin sustainability.
Negative Factors
Persistent Cash Burn
Multi-year negative operating and free cash flow shows the business is not self-funding and will require external capital until profitability. Continued burn erodes flexibility, raises dilution risk, and makes sustained investment in commercial expansion contingent on financing.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained gross margins near 70% indicate the core products have durable unit economics and pricing power. If management controls SG&A and R&D, high gross margins create a realistic path to profitability as volumes scale, supporting long-term margin sustainability.
Read all positive factors
Milestone Scientific (MLSS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$22.69M
Dividend YieldN/A
Average Volume (3M)172.66K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth0.59%
EPS Growth-39.76%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.02
Shares Outstanding80,453,120
10 Day Avg. Volume233,274
30 Day Avg. Volume172,658
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)7.97
Price to Sales (P/S)2.50
P/FCF Ratio-7.64
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.46
Enterprise Value/Gross Profit3.45
Enterprise Value/Ebitda-3.93
Forecast
1Y Price Target
$1.00Price Target Upside244.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$9.91M
Milestone Scientific Business Overview & Revenue Model
Company Description
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segm...
Milestone Scientific Earnings Call Summary
Earnings Call Date:Mar 31, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 14, 2026
Earnings Call Sentiment Neutral
The call highlighted clear progress: restructuring and cost actions led to improved operating losses, modest revenue growth, renewed commercial focus (digital marketing, Ambassador program) and an actionable plan for CompuFlo reimbursement and market expansion. Management provided concrete 2026 guidance ($9.8M–$10.2M) and a target to reach cash flow breakeven by early 2027. However, significant risks remain — cash on hand is limited ($1.1M), the company remains loss-making (full-year net loss $5.7M), gross profit was flat year-over-year, and key upside depends on regulatory approvals, reimbursement expansion and successful conversion of early commercial programs. Overall, positives and improvements are tangible but balanced by near-term liquidity and execution risks.Positive Updates
Revenue Growth — Q4 and Full Year 2025
Total revenue for Q4 2025 was $2.1M, up 2.2% ($45k) versus Q4 2024. Full-year net sales were $9.0M, up 4% from $8.6M in 2024.
Negative Updates
Low Cash Position and Leverage
As of December 31, 2025, the company reported only $1.1M in cash and $800k in debt, creating a limited near-term liquidity cushion despite management's stated stewardship and cost control.
Read all updates
Q4-2025 Updates
Positive
Negative
Revenue Growth — Q4 and Full Year 2025
Total revenue for Q4 2025 was $2.1M, up 2.2% ($45k) versus Q4 2024. Full-year net sales were $9.0M, up 4% from $8.6M in 2024.
Read all positive updates
Company Guidance
The company guided 2026 total revenue of $9.8–$10.2 million (double‑digit YoY growth) that assumes CompuFlo contribution of $500–$600K (≈400% increase vs. 2025) and expects gross margins to remain around the ~70% range; management said this top‑line growth, combined with 2025 cost actions, should meaningfully improve operating leverage, materially reduce cash burn and target cash‑flow breakeven in early 2027. Key program metrics referenced: dental penetration still <2% of the U.S. market, the Wand Ambassador pilot (launched Dec, national in Jan ’26) has ~175 ambassadors and ~30 demos to date with an expected “few hundred thousand dollars” of incremental 2026 sales; CompuFlo commercialization includes >10 physician Advisor partners, two 20+‑year Medicare consultants plus a 3–4 person reimbursement call center, presence in 3 MACs with expansion into additional MACs, and pursuit of broader Medicare and VA channels. Contextual 2025 results noted against the guidance: full‑year net sales $9.0M (up 4% from $8.6M), gross profit $6.4M (flat), operating loss improved to $5.7M from $6.8M, Q4 revenue $2.1M (up 2.2%) and Q4 operating loss $1.1M (an $953K, 89% improvement), with $1.1M cash and $800K debt as of 12/31/2025; international registrations in Japan, India and Mexico are ~85–90% complete but not assumed in the current guidance.Milestone Scientific Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.97M | 8.63M | 9.83M | 8.81M | 10.30M |
| Gross Profit | 6.41M | 6.43M | 6.79M | 4.90M | 6.31M |
| EBITDA | -5.62M | -6.72M | -7.04M | -8.76M | -7.30M |
| Net Income | -5.72M | -4.71M | -6.93M | -8.71M | -6.82M |
Balance Sheet | |||||
| Total Assets | 7.81M | 9.80M | 11.37M | 13.70M | 19.81M |
| Cash, Cash Equivalents and Short-Term Investments | 1.11M | 3.26M | 5.95M | 8.72M | 14.76M |
| Total Debt | 1.02M | 349.05K | 395.98K | 497.04K | 586.59K |
| Total Liabilities | 4.99M | 3.96M | 3.36M | 3.70M | 3.59M |
| Stockholders Equity | 2.81M | 5.83M | 8.01M | 10.23M | 16.37M |
Cash Flow | |||||
| Free Cash Flow | -2.93M | -2.93M | -5.33M | -6.04M | -4.03M |
| Operating Cash Flow | -2.92M | -2.92M | -5.33M | -6.03M | -4.02M |
| Investing Cash Flow | -15.12K | 2.97M | -2.97M | -8.53K | -15.19K |
| Financing Cash Flow | 786.34K | 233.77K | 2.56M | -8.54K | 4.57M |
Milestone Scientific Technical Analysis
Positive
0.29
Price Trends
0.28
Positive
0.30
Negative
0.43
Negative
Market Momentum
<0.01
Negative
52.01
Neutral
45.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLSS, the sentiment is Positive. The current price of 0.29 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.28, and below the 200-day MA of 0.43, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.01 is Neutral, neither overbought nor oversold. The STOCH value of 45.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MLSS.
Milestone Scientific Risk Analysis
Milestone Scientific disclosed 34 risk factors in its most recent earnings report. Milestone Scientific reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Milestone Scientific Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $29.59M | 43.37 | 12.22% | ― | 32.36% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $22.69M | -3.92 | -164.78% | ― | 0.59% | -39.76% | |
45 Neutral | $42.62M | -4.53 | -60.56% | ― | 13.67% | -37.01% | |
45 Neutral | $6.76M | -4.22 | -55.33% | ― | 73.38% | 34.87% | |
43 Neutral | $20.69M | -1.84 | -8.13% | ― | -0.95% | 58.17% | |
42 Neutral | $23.72M | -1.22 | -534.91% | ― | 63.53% | 12.49% |
* Healthcare Sector Average
MLSS
Milestone Scientific
0.28
-0.60
-68.03%
RVP
Retractable Technologies
0.69
>-0.01
-1.14%
POCI
Precision Optics Corporation
3.90
-0.34
-8.02%
NEPH
Nephros
2.78
0.97
53.59%
FEMY
Femasys
0.39
-0.73
-65.00%
NXGL
NexGel Inc
0.61
-2.01
-76.68%
Milestone Scientific Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Milestone Scientific Amends Agreement to Enhance Financing Flexibility
Positive
Apr 2, 2026
On March 31, 2026, Milestone Scientific Inc. amended a previously executed Amended and Restated Memorandum of Understanding dated January 13, 2026 with Innovest S.p.A., which holds consent and blockage rights tied to BP4 S.r.l., then the reported ...
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Milestone Scientific Increases Authorized Common Shares for Flexibility
Neutral
Mar 11, 2026
At its annual meeting on December 18, 2025, Milestone Scientific Inc. stockholders approved an amendment to the company’s Restated Certificate of Incorporation to increase its authorized common shares from 100 million to 125 million. Followi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.